Burhanettin Yalçınkaya1, Didem Tastekin2, Fatih Güzelbulut3, Muslum Akgoz1, Sadrettin Pençe4. 1. TUBITAK National Metrology Institute - Kocaeli, Turkey. 2. Istanbul University, Institute of Oncology - Istanbul, Turkey. 3. University of Health Sciences, Haydarpaşa Numune Training and Research Hospital - Istanbul, Turkey. 4. Istanbul Medeniyet University, Faculty of Medicine - Istanbul, Turkey.
Abstract
OBJECTIVE: Hepatocellular carcinoma is the most common primary malignant liver tumor. Mitochondrial DNA copy number has been shown to be associated with various malignancies. However, there has not been any study on the absolute quantification of mtDNA copy number in hepatocellular carcinoma. The aim of this study was to develop a new method for absolute quantification of mtDNA copy number and to relatively quantify the variations in the mtDNA copy number in hepatocellular carcinoma patients in comparison with healthy individuals. METHODS: Venous blood samples were collected from both hepatocellular carcinoma patients (34) and healthy individuals (34). Circulating cell-free DNAs were isolated and the relative quantification of mtDNA copy number variation was determined using quantitative polymerase chain reaction and digital polymerase chain reaction. RESULTS: It was found that the relative mtDNA copy number was significantly decreased in hepatocellular carcinoma patients in comparison with the control group (p<0.05). The median (range) and average of relative mtDNA/β-actin gene of the patients were determined as 42.8 cp/μL (11.1-88.5) and 45.1 cp/μL, respectively, while the median (range) and average relative mtDNA/β-actin gene of the control group were determined as 102.8 cp/μL (55.1-291.8) and 138.7 cp/μL, respectively (p<0.05). When quantitative polymerase chain reaction and digital polymerase chain reaction were compared, mtDNA/β-actin gene copy number ratio of digital polymerase chain reaction results was found to be 1.76-fold more than that of quantitative polymerase chain reaction results. CONCLUSION: Circulating mtDNA copy number was decreased in hepatocellular carcinoma patients in comparison with healthy individuals, and we suggest that it can be used as a noninvasive biomarker for hepatocellular carcinoma diagnosis in the future.
OBJECTIVE: Hepatocellular carcinoma is the most common primary malignant liver tumor. Mitochondrial DNA copy number has been shown to be associated with various malignancies. However, there has not been any study on the absolute quantification of mtDNA copy number in hepatocellular carcinoma. The aim of this study was to develop a new method for absolute quantification of mtDNA copy number and to relatively quantify the variations in the mtDNA copy number in hepatocellular carcinoma patients in comparison with healthy individuals. METHODS: Venous blood samples were collected from both hepatocellular carcinoma patients (34) and healthy individuals (34). Circulating cell-free DNAs were isolated and the relative quantification of mtDNA copy number variation was determined using quantitative polymerase chain reaction and digital polymerase chain reaction. RESULTS: It was found that the relative mtDNA copy number was significantly decreased in hepatocellular carcinoma patients in comparison with the control group (p<0.05). The median (range) and average of relative mtDNA/β-actin gene of the patients were determined as 42.8 cp/μL (11.1-88.5) and 45.1 cp/μL, respectively, while the median (range) and average relative mtDNA/β-actin gene of the control group were determined as 102.8 cp/μL (55.1-291.8) and 138.7 cp/μL, respectively (p<0.05). When quantitative polymerase chain reaction and digital polymerase chain reaction were compared, mtDNA/β-actin gene copy number ratio of digital polymerase chain reaction results was found to be 1.76-fold more than that of quantitative polymerase chain reaction results. CONCLUSION: Circulating mtDNA copy number was decreased in hepatocellular carcinoma patients in comparison with healthy individuals, and we suggest that it can be used as a noninvasive biomarker for hepatocellular carcinoma diagnosis in the future.
Authors: Gábor Zsurka; Miriam Baron; Joanna D Stewart; Cornelia Kornblum; Monika Bös; Robert Sassen; Robert W Taylor; Christian E Elger; Patrick F Chinnery; Wolfram S Kunz Journal: J Neuropathol Exp Neurol Date: 2008-09 Impact factor: 3.685
Authors: Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour Journal: J Hepatocell Carcinoma Date: 2016-10-05
Authors: Wei Wei; Michael J Keogh; Ian Wilson; Jonathan Coxhead; Sarah Ryan; Sara Rollinson; Helen Griffin; Marzena Kurzawa-Akanbi; Mauro Santibanez-Koref; Kevin Talbot; Martin R Turner; Chris-Anne McKenzie; Claire Troakes; Johannes Attems; Colin Smith; Safa Al Sarraj; Christopher M Morris; Olaf Ansorge; Stuart Pickering-Brown; James W Ironside; Patrick F Chinnery Journal: Acta Neuropathol Commun Date: 2017-02-02 Impact factor: 7.801
Authors: Jessica L Petrick; Peter T Campbell; Jill Koshiol; Jake E Thistle; Gabriella Andreotti; Laura E Beane-Freeman; Julie E Buring; Andrew T Chan; Dawn Q Chong; Michele M Doody; Susan M Gapstur; John Michael Gaziano; Edward Giovannucci; Barry I Graubard; I-Min Lee; Linda M Liao; Martha S Linet; Julie R Palmer; Jenny N Poynter; Mark P Purdue; Kim Robien; Lynn Rosenberg; Catherine Schairer; Howard D Sesso; Rashmi Sinha; Meir J Stampfer; Marcia Stefanick; Jean Wactawski-Wende; Xuehong Zhang; Anne Zeleniuch-Jacquotte; Neal D Freedman; Katherine A McGlynn Journal: Br J Cancer Date: 2018-03-09 Impact factor: 7.640
Authors: Cornelia Kornblum; Thomas J Nicholls; Tobias B Haack; Susanne Schöler; Viktoriya Peeva; Katharina Danhauser; Kerstin Hallmann; Gábor Zsurka; Joanna Rorbach; Arcangela Iuso; Thomas Wieland; Monica Sciacco; Dario Ronchi; Giacomo P Comi; Maurizio Moggio; Catarina M Quinzii; Salvatore DiMauro; Sarah E Calvo; Vamsi K Mootha; Thomas Klopstock; Tim M Strom; Thomas Meitinger; Michal Minczuk; Wolfram S Kunz; Holger Prokisch Journal: Nat Genet Date: 2013-01-13 Impact factor: 38.330